Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00555165
Other study ID # IMT-UK
Secondary ID
Status Completed
Phase N/A
First received November 5, 2007
Last updated November 13, 2012
Start date November 2007
Est. completion date May 2011

Study information

Verified date November 2012
Source VisionCare Ophthalmic Technologies, Inc.
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Evaluation of pre and post−implantation management of patients with end−stage age−related macular degeneration (AMD) who have been implanted with the implantable telescope (IMT) under CE Mark indicated use. This study is designed to evaluate in particular the optimal parameters for patient selection for use of this device in routine clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 55 Years and older
Eligibility Inclusion Criteria:

CE Mark approved indication of use which includes

- At least 55 years of age

- Bilateral visual impairment due to geographic atrophy or disciform scars

- Evidence of cataract

Exclusion Criteria:

- Active CNV (or 'wet' AMD)

- Prior cataract or refractive surgery in the study eye

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Telescope prosthesis
Monocular implantation of the telescope prosthesis after cataract extraction

Locations

Country Name City State
United Kingdom Royal Hospitals, Belfast Health & Social Care Trust Belfast
United Kingdom Frimley Park Hospital NHS Trust Frimley Surrey
United Kingdom King's College Hospital NHS Trust London
United Kingdom Moorfields Eye Hospital NHS Trust London

Sponsors (1)

Lead Sponsor Collaborator
VisionCare Ophthalmic Technologies, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best-Corrected Visual Acuity 1 year No
Secondary Quality of Life 1 year No